Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial

Publication | Closed Access

DOI

279

Citations

References

2014

Year

Mark Sulkowski, Christophe Hézode, Jan Gerstoft, John M. Vierling, Josep Mallolas, Stanislas Pol, Marcelo Kugelmas, Abel Murillo, Nina Weis, Ronald Nahass,

The Lancet

Open-label Phase 2Hepatitis CViral HepatitisAntiviral Drug DevelopmentAntiviral TherapyHepatitisVirologyChronic Viral InfectionAntiviral DrugHivMedicine